UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 93

Sortiert nach

Oral antiseptics against coronavirus: in-vitro and clinical evidence

The Journal of hospital infection, 2021-07, Vol.113, p.30-43

2021

Link zum Volltext

Verfügbarkeit prüfen

Selective localization of phosphatidylcholine-derived signaling in detergent-resistant membranes from synaptic endings

Biochimica et biophysica acta, 2010-03, Vol.1798 (3), p.624-636

2010

Link zum Volltext

Verfügbarkeit prüfen

PSY7 Budget Impact Analysis of Bendamustine in the Treatment of Multiple Myeloma in Spain

Value in health, 2011, Vol.14 (7), p.A411-A411

2011

Link zum Volltext

Verfügbarkeit prüfen

MC13-0007 Metabolomic profile of multiple myeloma patients

European journal of cancer (1990), 2013-11, Vol.49, p.S14-S14

2013

Link zum Volltext

Verfügbarkeit prüfen

Challenges and Solutions with First-generation Proteasome Inhibition: Practical Strategies

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e13-e13

2015

Link zum Volltext

Verfügbarkeit prüfen

Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma

Value in health, 2014-11, Vol.17 (7), p.A546-A546

2014

Link zum Volltext

Verfügbarkeit prüfen

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2017-07, Vol.28 (suppl_4), p.iv52-iv61

2017

Link zum Volltext

Verfügbarkeit prüfen

Amiloride induces potent antitumoral activity in multiple myeloma through the reactivation of mutant p53

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e251-e251

2015

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib in multiple myeloma

Best practice & research. Clinical haematology, 2007-12, Vol.20 (4), p.701-715

2007

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Antimyeloma Activity of EDO-S101

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e218-e218

2015

Link zum Volltext

Verfügbarkeit prüfen

Filanesib (ARRY-520) Demonstrates Potent and Rapid Activity in Preclinical Models of MM, Dependent on Bcl-2 Family Expression, and Synergistic with Dexamethasone and IMiDs

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e213-e214

2015

Link zum Volltext

Verfügbarkeit prüfen

Treatment of renal failure in patients with newly diagnosed multiple mieloma with bortezomib and dexamethasone: results of a phase II trial from PETHEMA/GEM group (RENVEL)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e256-e257

2015

Link zum Volltext

Verfügbarkeit prüfen

Flow Cytometry for Minimal Residual Disease

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e5-e5

2015

Link zum Volltext

Verfügbarkeit prüfen

Two randomized open-label studies of daratumumab (DARA) plus standard of care treatment versus standard of care alone in patients with previously untreated multiple myeloma (MM) ineligible for high-dose therapy: 54767414MMY3007 (Alcyone) and 54767414MMY3008 (Maia)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e294-e295

2015

Link zum Volltext

Verfügbarkeit prüfen

Outcome of Patients with Extramedullary Plasmacytomas (EMPs) Included in a Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e100-e100

2015

Link zum Volltext

Verfügbarkeit prüfen

Dexamethasone as a partner of isatuximab

Blood, 2021-03, Vol.137 (9), p.1133-1134

2021

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous Bortezomib Plus Melphalan and Prednisone (VMP) in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) Patients: Spanish Experience

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e135-e136

2015

Link zum Volltext

Verfügbarkeit prüfen

Pretransplant induction with VTD (Bortezomib/Thalidomide/Dexamethasone) significantly improves PFS: long-term results of the randomized phase 3 PETHEMA/GEM study

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e49-e50

2015

Link zum Volltext

Verfügbarkeit prüfen

Immunoparesis Recovery as Predictor Marker of Progression After Autologous Stem Cell Transplantation in Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.S51-S51

2015

Link zum Volltext

Verfügbarkeit prüfen

Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e127-e128

2015

Link zum Volltext

Verfügbarkeit prüfen

EE73 Ocean (OP-103): Patients with Relapsed/Refractory Multiple Myeloma Treated with Melflufen Plus Dexamethasone or Pomalidomide Plus Dexamethasone - a Resource Utilization Analysis of Adverse Events Leading to Hospitalizations

Value in health, 2023-12, Vol.26 (12), p.S64

2023

Link zum Volltext

Verfügbarkeit prüfen

HPR9 Value Criteria for Outcomes Based Managed Entry Agreement of CAR-T in Relapsed or Refractory Multiple Myeloma (RRMM) through MCDA

Value in health, 2023-12, Vol.26 (12), p.S256

2023

Link zum Volltext

Verfügbarkeit prüfen

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Leukemia, 2014-08, Vol.28 (8), p.1573-1585

2014

Link zum Volltext

Verfügbarkeit prüfen

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Leukemia, 2014-02, Vol.28 (2), p.391-397

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(93)

Publikationsform

Artikel
(93)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(25)
Hematology, Oncology And Palliative Medicine
(18)
Humans
(14)
Hematology
(10)
Male
(9)
Oncology
(9)
Biological And Medical Sciences
(8)
Female
(8)
Medical Sciences
(7)
Middle Aged
(7)
Multiple Myeloma
(7)
Adult
(6)
Animals
(6)
Agriculture
(5)
Spain
(5)
Agriculture, Dairy & Animal Science
(4)
Bone Marrow
(4)
Care And Treatment
(4)
Internal Medicine
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oral antiseptics against coronavirus: in-vitro and clinical evidence

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN‐COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL‐1)

Selective localization of phosphatidylcholine-derived signaling in detergent-resistant membranes from synaptic endings

PSY7 Budget Impact Analysis of Bendamustine in the Treatment of Multiple Myeloma in Spain

MC13-0007 Metabolomic profile of multiple myeloma patients

Challenges and Solutions with First-generation Proteasome Inhibition: Practical Strategies

Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Amiloride induces potent antitumoral activity in multiple myeloma through the reactivation of mutant p53

Bortezomib in multiple myeloma

Preclinical Antimyeloma Activity of EDO-S101

Filanesib (ARRY-520) Demonstrates Potent and Rapid Activity in Preclinical Models of MM, Dependent on Bcl-2 Family Expression, and Synergistic with Dexamethasone and IMiDs

Treatment of renal failure in patients with newly diagnosed multiple mieloma with bortezomib and dexamethasone: results of a phase II trial from PETHEMA/GEM group (RENVEL)

Flow Cytometry for Minimal Residual Disease

Two randomized open-label studies of daratumumab (DARA) plus standard of care treatment versus standard of care alone in patients with previously untreated multiple myeloma (MM) ineligible for high-dose therapy: 54767414MMY3007 (Alcyone) and 54767414MMY3008 (Maia)

Outcome of Patients with Extramedullary Plasmacytomas (EMPs) Included in a Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Dexamethasone as a partner of isatuximab

Subcutaneous Bortezomib Plus Melphalan and Prednisone (VMP) in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) Patients: Spanish Experience

Pretransplant induction with VTD (Bortezomib/Thalidomide/Dexamethasone) significantly improves PFS: long-term results of the randomized phase 3 PETHEMA/GEM study

Immunoparesis Recovery as Predictor Marker of Progression After Autologous Stem Cell Transplantation in Multiple Myeloma

Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study

EE73 Ocean (OP-103): Patients with Relapsed/Refractory Multiple Myeloma Treated with Melflufen Plus Dexamethasone or Pomalidomide Plus Dexamethasone - a Resource Utilization Analysis of Adverse Events Leading to Hospitalizations

HPR9 Value Criteria for Outcomes Based Managed Entry Agreement of CAR-T in Relapsed or Refractory Multiple Myeloma (RRMM) through MCDA

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Suchergebnisse filtern